From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution.
Open accessThe DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Identification of subjects at the early stages of Alzheimer's disease (AD) is fundamental for drug development and possible intervention or prevention of cognitive decline. The concept of mild cognitive impairment (MCI) evolved during the past two decades to define subjects at the transitional stage between normal aging and dementia. Evidence from cross-sectional and longitudinal studies has shown that MCI is associated with an increased risk of positive AD biomarkers and an increased annual conversion rate of 5%-17% to AD. The presence of AD biomarkers in subjects with MCI was associated with an even higher risk of progression to dementia. However, earlier clinical trials for pharmacotherapy in subjects with MCI were disappointing. To extend the spectrum of AD to an earlier stage before MCI, subjective cognitive decline (SCD) was introduced and was defined as self-reported cognitive decline before the deficits could be detected by cognitive tests. Subjects with SCD have an increased risk of underlying AD pathology. However, SCD can also develop secondary to other heterogeneous etiologies, including other neurodegenerative and psychiatric diseases, personality traits, physical conditions, and medication use. Several clinical and biomarker features were proposed to predict risk of conversion to AD in subjects with SCD. Further longitudinal studies are needed to support the validity of these high-risk features.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is informative for dementia research, since individuals with MCI have an increased annual conversion rate of 5–17% to Alzheimer’s disease (Cheng et al., 2017), and approximately 60% over a 15-year period of persons with SCD will continue to develop Alzheimer’s disease (Reisberg et al., 2008).”
From Mindfulness Training for People With Dementia and Their Caregivers: Rationale, Current Research, and Future Directions (2018) · cites this paper as Cheng et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 1×
“In 2011, the NIA-AA convened workgroups to revise diagnostic criteria for AD and its preclinical stages.(6,20,21) The NIA-AA core clinical criteria for MCI due to AD were essentially adopted from the Key Symposium criteria, while incorporation of biochemical and neuroimaging biomarkers was recommended in research sett…”
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2×
“The NIA-AA core clinical criteria for MCI due to AD were essentially adopted from the Key Symposium criteria, while incorporation of biochemical and neuroimaging biomarkers was recommended in research settings to stratify the level of certainty of underlying Alzheimer’s pathology.(21) During”
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864 · cited 1×
“To broaden the concept of MCI, the Key Symposium was held in Sweden and published consensus criteria for MCI in 2004.(10,11) To emphasize the heterogeneity of the clinical presentation and multiple underlying etiologies of MCI, the Key Symposium criteria expanded the definition of MCI beyond the memory domain and furt…”
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 3×
“Following the development of biochemical and neuroimaging biomarkers, the National Institute on Aging and the Alzheimer’s Association (NIA-AA) recommended a staging schema for preclinical AD based on biomarker status.(6) Subjects without cognitive decline are classified”
The Global Deterioration Scale for assessment of primary degenerative dementia
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.9.1136 · Cited by 4,986 · cited 1×
“that affect complex occupational and social activities but do not yet meet the criteria for dementia.(7,8) In 1999, Petersen et al redefined MCI as a syndrome of cognitive decline beyond that expected for an individual’s age and education level, but that does not notably interfere with activities of daily living.”
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946 · cited 1×
“To broaden the concept of MCI, the Key Symposium was held in Sweden and published consensus criteria for MCI in 2004.(10,11) To emphasize the heterogeneity of the clinical presentation and multiple underlying etiologies of MCI, the Key Symposium criteria expanded the definition of MCI beyond the memory domain and furt…”
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Cited by
Mild Cognitive Impairment in Clinical Practice: A Review Article
Jongsiriyanyong, S., & Limpawattana, P. (2018) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317518791401 · Cited by 457
Gómez‐Ramírez, J., Ávila‐Villanueva, M., & Fernández‐Blázquez, M. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-77296-4 · Cited by 127
Chopra, N., Wang, R., Maloney, B., Nho, K., Beck, J. S., Pourshafie, N., Niculescu, A., Saykin, A. J., Rinaldi, C., Counts, S. E., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0610-2 · Cited by 101
Franco, G. A., Interdonato, L., Cordaro, M., Cuzzocrea, S., & Paola, R. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087318 · Cited by 115
“SCD has been prospectively linked to underlying AD pathology, and it is thought to likely accelerate memory decline [61].”
BackgroundSubjective cognitive decline: preclinical manifestation of Alzheimer’s disease
Lin, Y., Shan, P., Jiang, W., Sheng, C., & Ma, L. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3620-y · Cited by 100
Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
Ray, B., Maloney, B., Sambamurti, K., Karnati, H. K., Nelson, P. T., Greig, N. H., & Lahiri, D. K. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0709-x · Cited by 91
Liu, J., Tao, J., Liu, W., Huang, J., Xue, X., Li, M., Yang, M., Zhu, J., Lang, C., Park, J., et al. (2019) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsz001 · Cited by 78
“The failure of treatments for MCI suggests that therapy should be applied in an earlier stage of the disease (Sperling et al., 2011; Cheng et al., 2017).”
BackgroundArlati, S., Santo, S. G. D., Franchini, F., Mondellini, M., Filiputti, B., Luchi, M., Ratto, F., Ferrigno, G., Sacco, M., & Greci, L. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201431 · Cited by 88
Desai, R., Whitfield, T. J., Said, G., John, A., Saunders, R., Marchant, N. L., Stott, J. C. H., & Charlesworth, G. M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101419 · Cited by 87
“The observation that in some instances SCD progresses to MCI which in turn may further progress to dementia has led some researchers to propose the continuum hypothesis of dementia (Cheng et al., 2017; Sperling et al., 2011).”
Granot‐Hershkovitz, E., Tarraf, W., Kurniansyah, N., Daviglus, M., Isasi, C. R., Kaplan, R., Lamar, M., Perreira, K. M., Wassertheil‐Smoller, S., Stickel, A., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12205 · Cited by 71
Lee, J., Fu, Z., Chung, M., Jang, D.-J., & Lee, H.-J. (2018) · Nutrition Journal · doi:10.1186/s12937-018-0387-1 · Cited by 70
“Most patients experience a subjective cognitive decline, also called subjective memory complaint, before noticeable cognitive impairment [7, 8].”
BackgroundSibilano, E., Brunetti, A., Buongiorno, D., Lassi, M., Grippo, A., Bessi, V., Micera, S., Mazzoni, A., & Bevilacqua, V. (2023) · Journal of Neural Engineering · doi:10.1088/1741-2552/acb96e · Cited by 84
“In particular, the boundary between SCD and MCI, which is the first clinically diagnosed stage of the disease, is very blurry [4].”
BackgroundKang, M. J., Kim, S., Na, D. L., Kim, B. C., Yang, D. W., Kim, E., Na, H. R., Han, H. J., Lee, J., Kim, J. H., et al. (2019) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-019-0974-x · Cited by 75
Le Page, A., Garneau, H., Dupuis, G., Frost, E. H., Larbi, A., Witkowski, J. M., Pawelec, G., & Fülöp, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00783 · Cited by 65
“Noticeably, the progression to full-blown AD is also relatively slow, occurring over a number of years (8).”
BackgroundCaillaud, M. L., Hudon, C., Boller, B., Brambati, S. M., Duchesne, S., Lorrain, D., Gagnon, J., Maltezos, S., Mellah, S., Phillips, N. A., et al. (2019) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbz120 · Cited by 79
“This is critical because disease-modifying treatments should ideally be offered as early as possible (Cheng et al., 2017).”
BackgroundBerk, L., Warmenhoven, F., van Os, J., & van Boxtel, M. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.00982 · Cited by 63
“This is informative for dementia research, since individuals with MCI have an increased annual conversion rate of 5–17% to Alzheimer’s disease (Cheng et al., 2017), and approximately 60% over a 15-year period of persons with SCD will continue to develop Alzheimer’s disease (Reisberg et al.”
BackgroundRecent Progress in the Pharmacotherapy of Alzheimer’s Disease
Khoury, R., Patel, K., Gold, J., Hinds, S., & Grossberg, G. T. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0499-x · Cited by 72
White Matter Microstructural Damage as an Early Sign of Subjective Cognitive Decline
Luo, C., Li, M., Qin, R., Chen, H., Yang, D., Huang, L., Liu, R., Xu, Y., Bai, F., & Zhao, H. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00378 · Cited by 62
“…or functional magnetic resonance imaging (MRI), fluorodeoxyglucose positron emission tomography (FDG-PET), and Pittsburgh compound B-positron emission tomography (PiB-PET) have provided substantial evidence that SCD is linked to underlying AD pathology (Sun et al., 2015; Cheng et al., 2017).”
BackgroundStructural and Functional Hippocampal Changes in Subjective Cognitive Decline From the Community
Liang, L., Zhao, L., Wei, Y., Mai, W., Duan, G., Su, J., Nong, X., Yu, B., Li, C., Mo, X., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00064 · Cited by 63
“Moreover, the difficulties of treating mild cognitive impairment (MCI) suggests that treatment should be applied at an earlier stage of the disease (Sperling et al., 2011; Cheng et al., 2017).”
BackgroundDemirayak, P., Kıyı, İ., Özbek, Y., & Yener, G. (2023) · Scientific Reports · doi:10.1038/s41598-023-43132-8 · Cited by 64
The factors associated with subjective cognitive decline and cognitive function among older adults
Lee, J., Sung, J., & Choi, M. (2019) · Journal of Advanced Nursing · doi:10.1111/jan.14261 · Cited by 63
Kim, J. H., Ahn, J. H., Min, C., Yoo, D. M., & Choi, H. G. (2021) · Sleep Medicine · doi:10.1016/j.sleep.2021.04.031 · Cited by 57
Petrazzuoli, F., Vestberg, S., Midlöv, P., Thulesius, H., Stomrud, E., & Palmqvist, S. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-191191 · Cited by 49
Stefanovski, L., Meier, J. M., Pai, R. K., Triebkorn, P., Lett, T. A. P., Martin, L., Bülau, K., Hofmann‐Apitius, M., Solodkin, A., McIntosh, A. R., et al. (2021) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2021.630172 · Cited by 55
MR‐assisted PET motion correction in simultaneous PET/MRI studies of dementia subjects
Chen, K. T., Salcedo, S., Chonde, D. B., Izquierdo‐Garcia, D., Levine, M. A., Price, J. C., Dickerson, B. C., & Catana, C. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26000 · Cited by 46
Lee, J. E., Ju, Y. J., Park, E., & Lee, S. Y. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.08.082 · Cited by 47
Effects of the FNDC5/Irisin on Elderly Dementia and Cognitive Impairment
Peng, J., & Wu, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.863901 · Cited by 49
Binnekade, T. T., Scherder, E., Maier, A. B., Lobbezoo, F., Overdorp, E. J., Rhebergen, D., Perez, R. S. G. M., & Oosterman, J. M. (2017) · Pain Medicine · doi:10.1093/pm/pnx162 · Cited by 32
Lazarou, I., Nikolopoulos, S., Dimitriadis, S. I., Kompatsiaris, I. Y., Spilioti, M. G., & Tsolaki, M. (2019) · Clinical Neurophysiology · doi:10.1016/j.clinph.2019.07.004 · Cited by 32
ReGAL 2.0 study group, Boccardi, V., Bubba, V., Murasecco, I., Pigliautile, M., Monastero, R., Cecchetti, R., Scamosci, M., Bastiani, P., & Mecocci, P. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01572-6 · Cited by 31
“Subjective cognitive decline (SCD) and mild cognitive impairment (MCI) are two classifications of prodromal Alzheimer’s dementia (AD) defined by symptom severity and neuropsychological performance [1].”
BackgroundForcano, L., Fauria, K., Soldevila‐Domenech, N., Minguillón, C., Lorenzo, T., Cuenca‐Royo, A., Menezes‐Cabral, S., Pizarro, N., Boronat, A., Molinuevo, J. L., et al. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12155 · Cited by 39
N-of-1 Clinical Trials in Nutritional Interventions Directed at Improving Cognitive Function
Soldevila‐Domenech, N., Boronat, A., Langohr, K., & de la Torre, R. (2019) · Frontiers in Nutrition · doi:10.3389/fnut.2019.00110 · Cited by 30
Shumbayawonda, E., López‐Sanz, D., Bruña, R., Serrano, N., Fernández, A., Maestú, F., & Abásolo, D. (2019) · Clinical Neurophysiology · doi:10.1016/j.clinph.2019.11.023 · Cited by 33
Uric acid and late-onset Alzheimer’s disease: results from the ReGAl 2.0 project
ReGAl 2.0 Study Group:, Boccardi, V., Carino, S., Marinelli, E., Lapenna, M., Caironi, G., Bianco, A. R., Cecchetti, R., Ruggiero, C., & Mecocci, P. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01541-z · Cited by 32
“AD is a complex degenerative brain disorder characterized by progressive impairment of all cognitive functions and conceptualized as a biological and clinical continuum from preclinical to the clinical or symptomatic phase where mild cognitive impairment (MCI) can be considered the prodromal phase of dementia as clini…”
BackgroundPereiro, A. X., Valladares‐Rodríguez, S., Felpete, A., Lojo‐Seoane, C., Campos‐Magdaleno, M., Mallo, S. C., Facal-Mayo, D., Anido, L., Belleville, S., & Juncos‐Rabadán, O. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210334 · Cited by 34
Establishment of a Risk Prediction Model for Mild Cognitive Impairment Among Elderly Chinese
Wang, B., Shen, T., Mao, L., Xie, L., Fang, Q., & Wang, X. (2020) · The journal of nutrition health & aging · doi:10.1007/s12603-020-1335-2 · Cited by 29
Association Between Subjective Cognitive Decline and Social and Emotional Support in US Adults
Weng, X., George, D. R., Jiang, B., & Wang, L. (2020) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317520922392 · Cited by 36
“Reducing SCD can also lead to other health benefits, because SCD itself is shown to significantly reduce quality of life, shorten life expectancy, and lead to other neurodegenerative diseases and psychiatric diseases.(10,17) Despite the usefulness of identifying risk factors for SCD, limited research exists in the lit…”
BackgroundKokubo, N., Yokoi, Y., Saitoh, Y., Murata, M., Maruo, K., Takebayashi, Y., Shinmei, I., Yoshimoto, S., & Horikoshi, M. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1795-7 · Cited by 28
The association between subjective cognitive decline and quality of life: A population-based study
Lee, S., & Chung, J. H. (2022) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2022.01.037 · Cited by 33
Carr, S., Pichora-Fuller, M. K., Li, K., Phillips, N. D., & Campos, J. L. (2019) · Multisensory Research · doi:10.1163/22134808-20191426 · Cited by 29
Ahn, S., Chung, J. W., Crouter, S. E., Lee, J., Lee, C. E., & Anderson, J. G. (2023) · Journal of Advanced Nursing · doi:10.1111/jan.15768 · Cited by 24
What are subjective cognitive difficulties and do they matter?
Opdebeeck, C., Yates, J., Kudlicka, A., & Martyr, A. (2018) · Age and Ageing · doi:10.1093/ageing/afy148 · Cited by 26
“Identification of factors associated with developing dementia is of clinical and research interest as it creates opportunity for early interventions [1, 2].”
BackgroundA Multifactor Approach to Mild Cognitive Impairment
Qarni, T., & Salardini, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678585 · Cited by 23
Marafioti, G., Culicetto, L., Latella, D., Marra, A., Quartarone, A., & Buono, V. L. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1549134 · Cited by 19
“…it remains uncertain whether SCD represents a distinct condition or reflects a combination of factors including emotional states such as depression (Kleineidam et al., 2023), systematic disease, the use of specific drugs, and neurodegenerative processes (Monahan et al., 2024; Cheng et al., 2017).”
Neurocognitive aging and cognitive disorders
Tabeeva, G. R. (2019) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2019119061160 · Cited by 41
Predementia neurocognitive impairment in the elderly
Levin, O. S. (2019) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro201911909210 · Cited by 21
Xu, L., Liu, F., Wang, B., Dong, R., Sun, L., Wang, M., & Bi, Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.680672 · Cited by 17
Pu, Z., Huang, H., Li, M., Li, H., Shen, X., Du, L., Wu, Q., Fang, X., Meng, X., Ni, Q., et al. (2025) · NeuroImage · doi:10.1016/j.neuroimage.2025.121130 · Cited by 18
“Cognitive impairment can be broadly categorized according to increasing severity as subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia (Cheng et al., 2017).”
Lazarou, I., Georgiadis, K., Nikolopoulos, S., Oikonomou, V. P., Stavropoulos, T. G., Tsolaki, A., Kompatsiaris, I. Y., & Tsolaki, M. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215421 · Cited by 20
Soldevila‐Domenech, N., Forcano, L., Boronat, A., Lorenzo, T., Piera, I., Puig‐Pijoan, A., Mateus, J., Gómez, J. M. G. D. E., Knezevic, I., Soteras, A., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201408 · Cited by 18
“Individuals with SCD are recognized as the optimal target population for dementia prevention trials [6].”
BackgroundGiacomucci, G., Galdo, G., Polito, C., Berti, V., Padiglioni, S., Mazzeo, S., Chiaro, E., Cristofaro, M. T. D., Bagnoli, S., Nacmias, B., et al. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113893 · Cited by 16
Li, Y., Kang, M., Wang, H., He, J., Wang, X., Gan, W., Zhao, M., Zhao, X. Q., Wang, R., & Han, Y. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190401 · Cited by 14
Dolcet-Negre, M. M., Imaz, L., de Eulate, M. R. G., Martí‐Andrés, G., Fernández‐Matarrubia, M., Domínguez, P. D., Fernández‐Seara, M. A., & Riverol, M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221002 · Cited by 17
Yu, Q., Jiang, X., Yan, J., & Yu, H. (2024) · Geriatric Nursing · doi:10.1016/j.gerinurse.2024.05.018 · Cited by 15
Bergamino, M., Keeling, E. G., McElvogue, M. M., Schaefer, S. Y., Burke, A. D., Prigatano, G. P., & Stokes, A. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230952 · Cited by 11
Gómez‐Soria, I., Ferreira, C., Oliván‐Blázquez, B., Aguilar‐Latorre, A., & Calatayud, E. (2023) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2023.104984 · Cited by 20
Exercise May Affect Metabolism in Cancer-Related Cognitive Impairment
Shahid, M., & Kim, J. (2020) · Metabolites · doi:10.3390/metabo10090377 · Cited by 14
Noh, D., & Shim, M. (2023) · Healthcare · doi:10.3390/healthcare11162341 · Cited by 12
“MCI is a transition stage between the cognitive decline expected in usual aging and the cognitive decline in dementia [7].”
BackgroundJang, H., Hill, N. L., Turner, J. R., Bratlee‐Whitaker, E., Jeong, M., & Mogle, J. A. (2024) · Innovation in Aging · doi:10.1093/geroni/igae038 · Cited by 11
“Reducing SCD can also lead to other health benefits because SCD itself significantly reduces quality of life, shortens life expectancy, and increases the risk of other neurodegenerative and psychiatric diseases (Cheng et al., 2017; Strand et al., 2018).”
BackgroundHsieh, C.-H., Ko, C.-A., Liang, C., Yeh, P.-K., Tsai, C., Tsai, C., Lin, G., Lin, Y., Tsai, M., & Yang, F. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1389595 · Cited by 12
Lazarou, I., Μoraitou, D., Papatheodorou, M., Vavouras, I., Lokantidou, C., Agogiatou, C., Gialaoutzis, M., Nikolopoulos, S., Stavropoulos, T. G., Kompatsiaris, I. Y., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210558 · Cited by 13
Marcotte, C., Potvin, O., Collins, D. L., Rheault, S., & Duchesne, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-49914-3 · Cited by 12
Methqal, I., Marsolais, Y., Wilson, M. A., Monchi, O., & Joanette, Y. (2018) · Aging Neuropsychology and Cognition · doi:10.1080/13825585.2017.1423021 · Cited by 10
Cognitive Performance Among Older Adults with Subjective Cognitive Decline
López-Higes, R., Rubio-Valdehita, S., López‐Sanz, D., Fernandes, S. M. S. R., Rodrigues, P. F. S., & Delgado‐Losada, M. L. (2025) · Geriatrics · doi:10.3390/geriatrics10020039 · Cited by 11
“…adults is understood as an early marker of cognitive impairment or neurodegeneration like Alzheimer’s Disease (AD) [4,5] since many reports have indicated that it is associated with an increased risk of clinical progression to mild cognitive impairment (MCI) in cognitively normal individuals [6,7].”
Liou, H., Stonnington, C. M., Shah, A. A., Buckner‐Petty, S., & Locke, D. E. C. (2021) · Brain Sciences · doi:10.3390/brainsci11101306 · Cited by 11
“Traditionally, mild cognitive impairment (MCI) has been the objectively-testable diagnosis used to describe patients in a transitional state between normal aging and dementia, most often due to Alzheimer’s disease (AD) [4].”
BackgroundPre-dementia cognitive impairment
Koberskaya, N. N., Mkhitaryan, E. A., Борисовна, Л. А., & Гришина, Д. А. (2022) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-1-2022-48-57 · Cited by 10
Liu, F., Xu, L., Lin, Y., Deng, X., Dong, R., Wang, B., & Bi, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.978297 · Cited by 9
“Presently, even though the discussion of SCD is more focused on a prodromal stage of Alzheimer’s disease (AD), SCD possibly serves more appropriately as a transition zone between the cognitive integrity phase and numerous potential cognitive deficits, including mild cognitive impairment (MCI) and various dementias(Che…”
BackgroundMicro RNA’s (mirna’s) may help explain expression of multiple genes in Alzheimer’s Frontal Cortex
Bennett, J. P., & Keeney, P. M. (2017) · Journal of Systems and Integrative Neuroscience · doi:10.15761/jsin.1000178 · Cited by 10
“AD progresses clinically through loss of one or more domains of cognition, known as mild cognitive impairment (MCI) [1-3].”
BackgroundThe Changing Profile of Patients in a Geriatric Medicine Led Memory Clinic over 12 Years
Chua, X. Y., Ha, N. H. L., Cheong, C. Y., Wee, S. L., & Yap, P. L. K. (2019) · The journal of nutrition health & aging · doi:10.1007/s12603-019-1161-6 · Cited by 9
DesRuisseaux, L. A., Suchy, Y., & Franchow, E. I. (2022) · The Clinical Neuropsychologist · doi:10.1080/13854046.2022.2055651 · Cited by 9
“Nevertheless, future research might examine whether subjective cognitive complaints, a known risk factor for future cognitive decline (Cheng et al., 2017; garcia-Ptacek et al., 2016; Mendonça et al., 2016), is associated with IIV-I and might in fact itself serve as a moderator of the association…”
BackgroundLópez-Higes, R., Rubio-Valdehita, S., Fernandes, S. M. S. R., & Rodrigues, P. F. S. (2024) · Geriatrics · doi:10.3390/geriatrics9030083 · Cited by 11
“Subjective cognitive decline (SCD) is associated with a three-to-six-fold increased risk of clinical progression to mild cognitive impairment (MCI) in cognitively healthy individuals [1,2].”
BackgroundValech, N., Sánchez‐Benavides, G., Tort‐Merino, A., Coll‐Padrós, N., Olives, J., León, M., Falcón, C., Molinuevo, J. L., & Rami, L. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190624 · Cited by 9
Pestana, P. C., Cardoso, S., Guerreiro, M., Marôco, J. P., Jessen, F., do Couto, F. S., & de Mendonça, A. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01634-1 · Cited by 12
MacDermott, S., McKechnie, R., LoGiudice, D., Morgan, D., & Blackberry, I. (2022) · Geriatrics · doi:10.3390/geriatrics7020035 · Cited by 10
“CI refers to changes in cognition across a spectrum ranging from normal age-related cognitive decline through to severe CI and includes, but is not limited to, diagnoses such as dementia and delirium [3,4].”
BackgroundTaguas, I., Doval, S., Maestú, F., & López‐Sanz, D. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01576-8 · Cited by 11
Osei, G. N., Bockarie, A. S., Akpalu, A. K., Adueming, P. O., Antwi, M. H., Appiah, F., Kpelle, L., Donkor, D. M., & Simpong, D. L. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70769 · Cited by 7
Wu, Y., Kong, Q., Li, Y., Feng, Y., Zhang, B., Liu, Y., Yu, S., Liu, J., Cao, J., Cui, F., et al. (2025) · Chinese Medicine · doi:10.1186/s13020-025-01106-0 · Cited by 9
“Both SCD and MCI significantly increase the risk of developing AD, highlighting their importance for early identification and intervention[27].”
Mohammad, D., Herrmann, N., Saleem, M., Swartz, R. H., OH, P. I., Bradley, J., Chan, P., Ellis, C., & Lanctôt, K. L. (2019) · BMC Geriatrics · doi:10.1186/s12877-019-1177-0 · Cited by 6
“Three items adapted from the six informant items of the General Practitioner Assessment of Cognition (GPCOG) were included to capture subjective memory complaints, a necessary symptom for the diagnosis of mild cognitive impairment [35].”
MethodHuang, J., Tang, J., Zhang, Y., Zhang, J., Tan, Z. T., & Shi, S. (2020) · European Neurology · doi:10.1159/000504844 · Cited by 8
Can RUDAS Be an Alternate Test for Detecting Mild Cognitive Impairment in Older Adults, Thailand?
Manjavong, M., Limpawattana, P., & Sawanyawisuth, K. (2021) · Geriatrics · doi:10.3390/geriatrics6040117 · Cited by 8
Zhan, S., Wang, J., Dong, J., Ji, X., Huang, L. T., Zhang, Q., Xu, D., Peng, L., Wang, X., Zhang, Y., et al. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104532 · Cited by 6
Cabaco, A. S., Torre, L. D. L., Núñez, D. Á., Mejía-Ramírez, M., & Sánchez, M. W. (2022) · PEC Innovation · doi:10.1016/j.pecinn.2022.100107 · Cited by 6
“Furthermore, although old age seems to be associated with an increase in the probability of suffering from certain diseases, as well as experiencing a relative intellectual decline, not all cases evolve similarly, so it is important to explore possible predictors of cognitive decline in the elderly [27,28].”
BackgroundJagtap, S., DAWSON, D. R., Vandermorris, S., Anderson, N. D., Davids-Brumer, N., Dar, M., Bernick, A., & Rotenberg, S. (2020) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acaa085 · Cited by 7
Han, Y., Zhu, B., Huang, D., Lan, Y., Zhong, H., Zhang, Y., Zhou, H., Liu, C., & Zhou, P. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07905-x · Cited by 11
“…decline is divided into subjective cognitive decline (SCD) and objective cognitive decline based on the presence or absence of abnormalities in neuropsychological tests and brain imaging examinations, and there is a strong link between them and mild cognitive impairment(MCI) and dementia [3, 4].”
Pu, Z., Huang, H., Li, M., Li, H., Shen, X., Wu, Q., Ni, Q., Lin, Y., & Cui, D. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1468246 · Cited by 10
Zhai, X., Wang, R., Liu, R., Jiang, D., & Yu, X. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06017-1 · Cited by 6
“The progression of cognitive impairment is usually a slow and continuous process, gradually developing from subjective cognitive decline (SCD) to MCI, and then to severe stages such as AD [8].”
Bergmann, C., Stögmann, E., & Lehrner, J. P. (2021) · Brain Disorders · doi:10.1016/j.dscb.2021.100014 · Cited by 5
Nanoengineered biomaterial for brain tissue reconstruction and functional repairment
Wong, F. S.-Y., Tsang, K. K., & Lo, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813355-2.00007-7 · Cited by 5
Wang, S., Park, S., Park, S. H., Kim, N.-Y., Kang, D. W., Na, H.-R., Bae, Y. Y., Lee, J. W., Han, S., & Lim, H. K. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.2.294 · Cited by 5
“To fill this gap, we aimed to investigate treatment outcome of patients with neurocognitive dysfunction after receiving HSCT. Neurocognitive dysfunction covers wide range of clinical syndrome from subjective cognitive decline, mild cognitive impairment, and to dementia [19].”
Manjavong, M., Limpawattana, P., & Sawanyawisuth, K. (2021) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000517821 · Cited by 8
Cognitive disorders in the middle-aged population and cerebrovascular risk factors
Gnedovskaya, E. V., Kravchenko, M. A., Nikolaeva, N. S., Чечеткин, А. О., Кротенкова, М. В., & Varakin, Y. Y. (2018) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro201811806227 · Cited by 4
Mild cognitive impairment: what's next?
Tabeeva, G. R. (2019) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2019119101103 · Cited by 4
Xu, Y., Wang, Y., Chen, Y., Zhang, Y., Li, T., He, Y. J., Fang, J., Li, R., Zhang, X., & Jin, L. (2023) · Clinical Gerontologist · doi:10.1080/07317115.2023.2282484 · Cited by 4
“SCD is hypothesized to accelerate memory deterioration and has been connected to the underlying pathophysiology of AD (Cheng et al., 2017; Flatt et al., 2018; Gallassi et al., 2010).”
Poonam, K., Prasad, A., Guha, R., Hazra, A., & Chakrabarti, P. P. (2023) · Lecture notes in computer science · doi:10.1007/978-3-031-45170-6_25 · Cited by 4
Altieri, M., Maggi, G., Giacobbe, C., & Santangelo, G. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07265-y · Cited by 4
“…refer to the individuals’ concerns about their own cognitive performance (especially memory failures but also attentional and thinking concerns as well as complaints on activities of daily living may be present) reported by people with and without objective evidence of cognitive impairment [1].”
InfluentialMai, W., Zhang, A., Liu, Q., Tang, L., Wei, Y., Su, J., Duan, G., Teng, J., Nong, X., Yu, B., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.773687 · Cited by 4
“2%, and its occurrence is more common in men and increases with age and lower education (Suzuki et al., 2013; Langa and Levine, 2014; Cheng et al., 2017; Petersen et al., 2018).”
BackgroundAllam, A. K., Allam, V., Reddy, S., ROHREN, E. M., Sheth, S. A., Froudarakis, E., & Papageorgiou, T. D. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0083 · Cited by 5
“(ii) Subjective cognitive impairment (SCI) , a prodromal phase of mild cognitive impairment (MCI) leading to Alzheimer’s disease [33], is characterized by cognitive decline without objective deficits upon neuropsychological testing or other neurological or psychiatric diagnoses [34–39].”
BackgroundFrech, F. H., Li, G., Juday, T. R., Ding, Y., Mattke, S., Khachaturian, A. S., Rosenberg, A. S., Ndiba-Markey, C., Rava, A. R., Batrla, R., et al. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.8.782 · Cited by 5
Zhang, Y., Lan, Y., Mou, Y., Deng, Y., Chen, Z., Fu, Y., Shi, Z., Zhang, L., & Zhao, Y. (2025) · Nutrients · doi:10.3390/nu17223529 · Cited by 3
“Alzheimer’s disease (AD) is the most common form of dementia [47], and its pathogenesis has been the most extensively studied.”
Romero, K., Coleman, A., Heir, A. S., Leach, L. R., & Proulx, G. B. (2022) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acac050 · Cited by 4
Metadata
- Authors
- Cheng, Y.-W., Chen, T.-F., & Chiu, M.-J.
- Affiliations
- National Taiwan University Hospital (TW)
- National Taiwan University (TW)
- Corresponding author
- Chiu, Ming-Jang
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2017-02
- Volume
- Volume 13
- Pages
- 491-498
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC5317337
- OpenAlex
- W2588980103
- Cited by
- 150
- References
- 98
- Citations by year
- 2026: 4 · 2025: 28 · 2024: 18 · 2023: 16 · 2022: 15 · 2021: 17 · 2020: 15 · 2019: 19 · 2018: 14 · 2017: 4
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- mild cognitive impairment, subjective cognitive decline, Alzheimer's disease, early detection of dementia, conversion to dementia, Alzheimer's disease biomarkers, risk prediction, normal aging, neurodegenerative diseases, drug development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.